Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells
Source abstract
Abstract
In this paper, a redox and enzyme dual-stimuli responsive delivery system (MSN-SS-HA) based on mesoporous silica nanoparticles (MSN) for targeted drug delivery has been developed, in which hyaluronic acid (HA) was conjugated on the surface of silica by cleavable disulfide (SS) bonds. HA possesses many attractive features, including acting as a targeting ligand and simultaneously a capping agent to achieve targeted and controlled drug release, prolonging the blood circulation time, and increasing the physiological stability and biocompatibility of MSN. The anticancer drug doxorubicin (DOX) was chosen as a model drug. In vitro drug release profiles showed that the release of DOX was markedly restricted in pH 7.4 and pH 5.0 phosphate buffer solution (PBS), while it was significantly accelerated upon the addition of glutathione (GSH)/hyaluronidases (HAase). In addition, the release was further accelerated in the presence of both GSH and HAase. Confocal laser scanning microscopy (CLSM) and fluorescence-activated cell sorting (FACS) showed that MSN-SS-HA exhibited a higher cellular uptake via cluster of differentiation antigen-44 (CD44) receptor-mediated endocytosis compared with thiol (SH)-functionalized MSN (MSN-SH) in CD44 receptor over-expressed in human HCT-116 cells. The DOX-loaded MSN-SS-HA was more cytotoxic against HCT-116 cells than NIH-3T3 (CD44 receptor-negative) cells due to the enhanced cellular uptake of MSN-SS-HA. This paper describes the development of an effective method for using a single substance as multi-functional material for MSN to simultaneously regulate drug release and achieve targeted delivery.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Proteoglycans and glycosaminoglycans research · Glycosylation and Glycoproteins Research · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (29)
Show source-provided references
1. Ordered mesoporous polymer-silica hybrid nanoparticles as vehicles for the intracellular controlled release of macromolecules10.1021/nn101740e ↗
2. Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics10.1002/ange.201002639 ↗
3. Redox and pH-responsive degradable micelles for dually activated intracellular anticancer drug release10.1016/j.jconrel.2013.01.001 ↗
4. Glutathione-triggered “Off–On” release of anticancer drugs from dendrimer-encapsulated gold nanoparticles10.1021/ja402903h ↗
5. The intracellular controlled release from bioresponsive mesoporous silica with folate as both targeting and capping agent10.1039/c2nr30425b ↗
6. Enzyme responsive nanocontainers with cyclodextrin gatekeepers and synergistic effects in release of guests10.1021/ja9061085 ↗
7. A light-responsive reversible molecule-gated system using thymine-modified mesoporous silica nanoparticles10.1021/la2047504 ↗
8. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery10.1016/j.jconrel.2011.01.030 ↗
9. Mesoporous silica nanoparticles capped with disulfide-linked PEG gatekeepers for glutathione-mediated controlled release10.1021/am3005225 ↗
10. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities10.1016/S0169-409X(02)00179-5 ↗
11. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery10.1016/j.biomaterials.2013.01.084 ↗
12. Polyvalent nucleic acid/mesoporous silica nanoparticle conjugates: dual stimuli-responsive vehicles for intracellular drug delivery10.1002/anie.201005471 ↗
13. Capped mesoporous silica nanoparticles as stimuli-responsive controlled release systems for intracellular drug/gene delivery10.1517/17425247.2010.498816 ↗
14. Hyaluronidases: their genomics, structures, and mechanisms of action10.1021/cr050247k ↗
15. Hyaluronan: from extracellular glue to pericellular cue10.1038/nrc1391 ↗
16. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy10.1021/nn202070n ↗
17. Structure of human hyaluronidase-1, a hyaluronan hydrolyzing enzyme involved in tumor growth and angiogenesis10.1021/bi700382g ↗
18. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells10.1021/mp800215d ↗
19. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors10.1016/j.biomaterials.2010.05.067 ↗
20. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel10.1016/j.biomaterials.2011.06.028 ↗
21. Bioresponsive hyaluronic acid-capped mesoporous silica nanoparticles for targeted drug delivery10.1002/chem.201202038 ↗
22. S-[2-(4-A zidosalicylamido) ethylthio]-2-thiopyridine: radioiodinatable, cleavable, photoactivatible cross-linking agent10.1021/bc9600168 ↗
23. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells10.1039/C2NR32145A ↗
24. The phase (trans) formation and physical state of a model drug in mesoscopic confinement10.1039/c1cp20874h ↗
25. Facile synthesis of pH sensitive polymer-coated mesoporous silica nanoparticles and their application in drug delivery10.1016/j.ijpharm.2011.10.013 ↗
26. Understanding controlled drug release from mesoporous silicates: theory and experiment10.1016/j.jconrel.2011.06.038 ↗
27. Modus operandi of controlled release from mesoporous matrices: a theoretical perspective10.1039/c1cp20636b ↗
28. Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: improved water suspensibility and decreased nonspecific protein binding10.1021/nn901376h ↗
29. Hyaluronic acid oligosaccharide modified redox-responsive mesoporous silica nanoparticles for targeted drug delivery10.1021/am505824d ↗